Aurora A/HDAC-IN-1
Aurora A/HDAC-IN-1 is an orally active dual inhibitor of Aurora A and pan-HDAC (IC50 = 5.61 μM and 0.31 μM). Aurora A/HDAC-IN-1 induces apoptosis and G2/M cell cycle arrest through downregulating p-Aurora A and increasing Ac-H3 and Ac-α-tubulin acetylation, and exhibits broad-spectrum antiproliferative activity. Aurora A/HDAC-IN-1 can be used for research on leukemia and colorectal cancer.
For research use only. We do not sell to patients.
- Formula: C26H25ClN4O4
- Molecular Weight:492.95
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Aurora Kinase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Aurora A 5.61 μM (IC50) |
HDAC 0.31 μM (IC50) |
α-Tubulin |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Jurkat | IC50 |
0.69 μM
|
Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay.
Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay.
|
42614924 |
| HCT-116 | IC50 |
1.84 μM
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay.
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay.
|
42614924 |
| HeLa | IC50 |
7.09 μM
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay.
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay.
|
42614924 |
| HepG2 | IC50 |
7.27 μM
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay.
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay.
|
42614924 |
| MCF7 | IC50 |
4.17 μM
|
Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay.
Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay.
|
42614924 |
| HUVEC | IC50 |
8.78 μM
|
Antiproliferative activity against normal human HUVECs assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay.
Antiproliferative activity against normal human HUVECs assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay.
|
42614924 |
In Vitro
Aurora A/HDAC-IN-1 (10 μM; 90 min) exhibits low to moderate inhibitory activity against Aurora A kinase with an IC50 of 5.61 μM[1].
Aurora A/HDAC-IN-1 (10 μM; 20 min) potently inhibits total HDAC enzyme activity with an IC50 of 0.31 μM[1].
Aurora A/HDAC-IN-1, as a pan-HDAC inhibitor, exhibits comparable inhibitory activity against class I (HDAC1, 2, 3) and class IIb (HDAC6, 10) subtypes, with IC50 values in the nanomolar range[1].
Aurora A/HDAC-IN-1 binds stably to both Aurora A and HDAC proteins, with binding free energies of −58.31 kcal mol-1 and −35.29 kcal mol-1, respectively[1].
Aurora A/HDAC-IN-1 (100 μM; 0-60 min) exhibits a short half-life (17.6 min) and a high intrinsic clearance (0.08 mL min-1 mg-1) in human liver microsomes, indicating rapid metabolism[1].
Aurora A/HDAC-IN-1 (compound Z20) (various concentrations; 48 h) exhibits potent broad-spectrum antiproliferative activity against Jurkat, HCT-116, HeLa, HepG2, and MCF-7 cell lines, with the highest activity against Jurkat cells (IC50 = 0.69 μM) and a wider therapeutic window than SAHA[1].
Aurora A/HDAC-IN-1 (0.03125-2 μM; 24 h) specifically downregulates p-Aurora A and increases Ac-H3 and Ac-α-tubulin levels in a concentration-dependent manner in both Jurkat and HCT116 cells, without affecting other Aurora family members or total Aurora protein levels[1].
Aurora A/HDAC-IN-1 (0.25-8 μM; 48 h) effectively induces apoptosis in Jurkat and HCT116 cells in a concentration-dependent manner[1].
Aurora A/HDAC-IN-1 (0.0625-1 μM; 48 h) induces G2/M phase arrest in Jurkat and HCT116 cells in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Jurkat and HCT116
-
Concentration:0.25, 0.5, 1, 2, and 4 μM (Jurkat); 0.5, 1, 2, 4, and 8 μM (HCT116)
-
Incubation Time:48 h
-
Result:Induced total apoptotic ratios of 13.39%, 22.2%, 48%, 97.56%, and 98.7% in Jurkat cells at 0.25, 0.5, 1, 2, and 4 μM, respectively.
Induced total apoptotic ratios of 9.68%, 18.46%, 39.6%, 50.6%, and 53.3% in HCT116 cells at 0.5, 1, 2, 4, and 8 μM, respectively.
-
Cell Line:Jurkat and HCT116
-
Concentration:0.0625, 0.125, 0.25, 0.5, and 1 μM
-
Incubation Time:48 h
-
Result:Increased the percentage of Jurkat cells arrested at the G2/M phase to 29.8%, 35%, 35.2%, 36%, and 37.1% at 0.0625, 0.125, 0.25, 0.5, and 1 μM, respectively.
-
Cell Line:Jurkat and HCT116
-
Concentration:0.03125, 0.0625, 0.125, 0.25, and 0.5 μM (for p-Aurora and total Aurora proteins); 0.125, 0.25, 0.5, 1, and 2 μM (for Ac-H3 and Ac-α-tubulin); gradient concentrations (HCT116)
-
Incubation Time:24 h
-
Result:Significantly downregulated p-Aurora A at 0.25 μM.
Did not significantly change p-Aurora B, p-Aurora C, total Aurora A, and total Aurora B levels.
Increased Ac-H3 and Ac-α-tubulin levels in a concentration-dependent manner.
Induced identical regulatory trends in HCT116 cells.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOG mice (six-week-old, female)[1]
-
Dosage:30; 60 mg/kg
-
Administration:i.g.; once daily; 16 consecutive days
-
Result:Inhibited tumor growth with TGI rates of 43.74% and 47.24% at 30 mg/kg and 60 mg/kg, respectively.
Induced tumor cell apoptosis and inhibited proliferation.
Did not cause significant organ toxicity.
Chemical Information
-
Molecular Weight 492.95
-
Formula C26H25ClN4O4
-
SMILES
ClC(C(OC1=NC=CC=C1)=C2)=CC=C2C3=CC(C(NCCCCC(NO)=O)=O)=C(C)C4=C3C=CN4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)